|
Getting your Trinity Audio player ready...
|
Halberd Corporation (OTC: HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC with their patented extracorporeal process and patent-pending laser eradication method in conjunction with metallic nanoparticles eliminated 99.5% of the bacteria from the sample in under 10 minutes.
Trading Activity
HALB stock was one of the notable gainers last week with a weekly gain of 50%. Moreover, On Friday, the stock went up 12.24% to close at $0.0165. The stock is trading above all the major moving averages including 50-day and 200-day of $0.0090 and $0.0119 respectively.
Not too long ago Halberd Corporation had been provided with a number of antibiotic resistant antigens by the CDC and had been tasked with the job of trying to eradicate those antigens using its own technology.
This morning the company announced that it had hit another milestone after it demonstrated the capability of eradicating a number of strains of E Coli, which is an antibiotic resistant antigen. The company had deployed its patented extracorporeal process and the laser eradication method, for which a patent is still pending. The company used those two technologies concurrently with metallic nanoparticles and had been able to eliminate as much as 99.5% of the bacteria from the given samples in less than 10 minutes.
Dr. Cooper, who is a professor at the Department of Chemical and Biological Sciences at Youngstown State University, had overseen in the entire process. He noted that the CDC had provided as many as 30 strains of antibiotic resistant bacteria and the university, in collaboration with Halberd’s technology, had managed to eliminate several of those. He went on to note that it was a ‘tremendous step forward’ and added that he was confident that the collaboration was going to continue to be successful.
The President, Chief Executive Officer and Chairman of the company William A Hartman spoke about the development as well. He stated that the ability to eradicate antibiotic resistant bacteria could have a major effect on the future of healthcare. It could not only lead to quicker treatments but also a lower number of hospitalization cases.
Related posts:
Human Unitec International, Inc. (OTCMKTS:HMNU) Announces Medical Equipment Deal in China Closed Up 17.78% 10x Volume: RSHN, ALST, HALB, EPAZ
Power 5 Pennies This Week: GEGR, ZRFY, HALB, GRST, HMNU
Halberd Corp (OTC:HALB) & Centers of Disease Control (CDC) to Discuss Results at Youngstown State University (YSU)
Halberd Corp (OTC:HALB) May Hold the Key in Candida Auris Fungus Breakout!
7 Stocks in the News This Week – HNRC, HALB, HRAL, PBIO, MWWC, FOBI.V / FOBIF, RGX.V/RGXTF